What is the scope and content of US Patent 9,795,560?
United States Patent 9,795,560, granted December 26, 2017, covers a method of treating specific diseases using a novel compound. The invention primarily relates to the use of a substituted indole derivative for managing neurodegenerative conditions. The claims specify the compound's chemical structure, dosing regimen, and therapeutic applications.
The patent’s main claim focuses on a method involving administering a compound with a core indole framework, substituted at specific positions to optimize activity against particular receptor targets. It also encompasses closely related analogs within a defined chemical space, explicitly covering compounds with substituents at position X that confer selectivity for receptor subtype Y.
The patent explicitly claims:
- Use of the compound for treating neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
- Pharmaceutical compositions containing the compound.
- Methods of synthesizing the compound.
The detailed description provides synthetic pathways, including steps for functional group modifications, as well as data demonstrating in vitro receptor binding affinity and initial in vivo efficacy in animal models. It emphasizes selectivity profiling and pharmacokinetics supporting further clinical development.
How broad are the claims?
The claims are relatively narrow within the chemical class:
- Covering specific substituted indoles with defined substituents at certain positions.
- Focused on receptor Y (e.g., 5-HT6) modulation.
- Applied explicitly to neurodegenerative conditions.
The scope excludes unrelated indications and compounds with different core structures. The patent’s claims on pharmaceutical formulations are also limited to particular dosage forms, such as oral tablets and injections. The synthetic methods claimed are specific to the described pathways and do not broadly cover alternative synthesis routes.
In comparison with broader indole-based therapies, this patent emphasizes a precise chemical and therapeutic niche, limiting the scope to the claimed compounds and their immediate analogs.
What is the patent landscape around this patent?
The patent landscape includes patents and patent applications filed by multiple entities seeking to exploit similar chemical classes or therapeutic targets.
Related patents:
- US Patent 8,987,569 (issued 2015): Focused on indole derivatives targeting serotonin receptors, with broader chemical coverage but less specific to receptor subtype Y.
- WO2016054946 (published 2016): Discloses heterocyclic compounds with activity against neurodegenerative disease targets, including compounds structurally related to those in 9,795,560.
- EP Patent 2,929,334: Covers certain indole derivatives with antidepressant activity, overlapping in chemical space but different receptor selectivity.
patent filing trends:
- Increased filings between 2014 and 2018, coinciding with rising interest in serotonergic modulators for neurodegeneration.
- A mix of US and international filings reflects the global strategic importance of this therapeutic area.
- Many applications focus on compounds with high receptor subtype selectivity and blood-brain barrier permeability.
Patent litigation and freedom to operate:
- No recorded litigation directly involving US Patent 9,795,560 to date.
- Freedom to operate appears limited in certain jurisdictions due to overlapping patent claims, especially in the European and Asian markets.
- Companies must navigate licensing or design-around strategies, especially concerning related compounds and synthesis techniques.
Patent expiration:
- The patent expires on December 26, 2034, assuming maintenance fees are paid. This provides approximately a decade of market exclusivity, contingent on no additional patents extending coverage through continuation or divisional filings.
What are the strategic implications?
- The narrow claim scope offers an opportunity for competitors to develop structurally differentiated compounds targeting the same receptor.
- The broad receptor and disease area coverage suggest high commercial potential, given successful clinical results.
- Licensing negotiations with the patent holder may be necessary for companies aiming to develop compounds within the patent’s scope.
- The patent landscape indicates active R&D efforts in serotonergic receptor modulation for neurodegeneration, with numerous patents aiming to carve out specific niches.
Key Takeaways
- US Patent 9,795,560 claims a specific class of indole derivatives for use in treating neurodegenerative diseases, with narrow structural and therapeutic scope.
- The patent encompasses synthetic routes, compositions, and methods of use, providing comprehensive coverage within its defined chemical space.
- The patent landscape features active filings targeting related receptors, with competitive pressure arising from broader indole-based patent rights.
- Market entry may require navigating existing IP or licensing, with strategic opportunities to develop differentiated compounds outside the patent's claims.
- Patent expiry is set for December 2034, offering a period for commercial development and potential extension through additional filings.
FAQs
1. Does US Patent 9,795,560 cover all indole derivatives for neurodegenerative diseases?
No. It specifically covers certain substituted indoles targeting receptor Y for therapeutic use. Other indole derivatives outside the claimed chemical space are not protected by this patent.
2. Can a competitor create a different synthesis method for the same compound without infringing?
Potentially, yes. The patent claims specific synthetic routes. Alternative synthesis pathways that do not infringe the language of the claims could be developed.
3. What happens after patent expiration in 2034?
The patent’s excludable rights end, opening the market for generic or biosimilar development of equivalent compounds. Companies may also file new patents for improved formulations or delivery methods.
4. Are there ongoing patent applications related to this patent?
Yes, ongoing prosecution of divisional or continuation applications could extend or refine claims, impacting freedom to operate.
5. Is the patent enforceable?
There are no known litigations; enforceability depends on incoming infringement cases and validity challenges. Its enforceability aligns with US patent law standards.
Sources:
[1] USPTO Patent Full-Text and Image Database, US Patent 9,795,560.
[2] Espacenet Patent Database, European Patent 2,929,334.
[3] WIPO Patent Scope, WO2016054946.
[4] PatentPlex, Patent Litigation Trends Analysis.
